** Shares of medical device maker Tandem Diabetes Care TNDM.O down 24% at $25.50
** Company late on Wednesday forecast 2025 sales between $997 mln and $1.007 bln vs. analysts' average estimate of $1.004 billion, according to data compiled by LSEG
** Says "muted seasonality" and "shipping delays" led to softness in demand for co's insulin pumps towards the end of Q4 and expects salesforce disruptions -TNDM
** The 2025 outlook reflects the seasonal trends extending into Q1 - RBC Capital analysts
** "What will likely cause investor consternation is the lower-than-anticipated Q1 2025 revenue guidance and the implied ramp through the rest of the year" -Brokerage Citi
** Company sees Q1 sales to be about $219 million to $224 million compared to analysts' estimate of $221 million
** TNDM has risen 16.4% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。